Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Jatin Shah Biography and Net Worth

EVP of Karyopharm Therapeutics

As Karyopharm’s Executive Vice President, Chief Medical Officer, Dr. Jatin Shah is responsible for overseeing the company’s ongoing clinical programs.

Dr. Shah brings significant medical oncology experience to Karyopharm from his prior work at The University of Texas MD Anderson Cancer Center (MD Anderson), including work as a treating physician for patients with multiple myeloma and clinical research. For nearly ten years at MD Anderson, Dr. Shah served as an Associate Professor and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine.

Dr. Shah received his medical degree from Ohio State University College of Medicine, Columbus, Ohio, and his undergraduate degree, also from Ohio State University, in Mechanical Engineering. He completed an internship and residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr. Shah holds board certification in hematology and oncology from the American Board of Internal Medicine. He has served as principal investigator/co-investigator for numerous relapsed/refractory multiple myeloma studies and has published articles and abstracts in many peer-reviewed journals.

What is Jatin Shah's net worth?: The estimated net worth of Jatin Shah is at least $32,887.29 as of February 18th, 2021. Dr. Shah owns 51,791 shares of Karyopharm Therapeutics stock worth more than $32,887 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Shah may own. Learn More about Jatin Shah's net worth.
How do I contact Jatin Shah?: The corporate mailing address for Dr. Shah and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Jatin Shah's contact information.
Has Jatin Shah been buying or selling shares of Karyopharm Therapeutics?: Jatin Shah has not been actively trading shares of Karyopharm Therapeutics in the last ninety days. Most recently, Jatin Shah sold 1,704 shares of the business's stock in a transaction on Monday, February 7th. The shares were sold at an average price of $9.86, for a transaction totalling $16,801.44. Learn More on Jatin Shah's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Michael Kauffman (Director), Michael Mason (CFO), Stephen Mitchener (SVP), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, insiders at the sold shares 23 times. They sold a total of 1,461,709 shares worth more than $1,454,603.97. The most recent insider tranaction occured on October, 4th when CEO Richard A Paulson sold 3,607 shares worth more than $3,174.16. Insiders at Karyopharm Therapeutics own 4.3% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 10/4/2024.

Jatin Shah Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/7/2022	Sell	1,704	$9.86	$16,801.44
5/7/2021	Buy	23,250	$8.60	$199,950.00
2/18/2021	Sell	1,186	$14.83	$17,588.38	51,791
7/15/2020	Sell	589	$19.46	$11,461.94	43,172
2/19/2020	Sell	1,375	$16.48	$22,660.00	40,759

Jatin Shah Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $0.64

$0.63

$0.66

50 Day Range

MA: $0.82

$0.65

$0.99

2 Week Range

Now: $0.64

$0.63

$1.95

Volume

1,277,004 shs

Average Volume

1,221,216 shs

Market Capitalization

$80.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

First JFK… next Elon?

From Porter & Company | Ad